• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishDashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SC 13G filed by PolyPid Ltd.

    4/17/24 4:05:02 PM ET
    $PYPD
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $PYPD alert in real time by email
    SC 13G 1 ea0204095-13glukach_polypid.htm SCHEDULE 13G

     

     

    SECURITIES AND EXCHANGE COMMISSION

    WASHINGTON, D.C. 20549

     

    SCHEDULE 13G 

     

    (Rule 13d-102)

     

    INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT

    TO § 240.13d-1(b), (c) AND (d) AND AMENDMENTS THERETO FILED

    PURSUANT TO § 240.13d-2

     

    (Amendment No.   )*

     

    PolyPid Ltd. 

    (Name of Issuer)

     

    Ordinary Shares, no par value 

    (Title of Class of Securities)

     

    M8001Q126 

    (CUSIP Number)

     

    Aharon Lukach

    c/o Eli Cohen 9, Tel Aviv, Israel, 6963005. 

    (Name, Address and Telephone Number of Person
    Authorized to Receive Notices and Communications)

     

    January 9, 2024 

    (Date of Event which Requires Filing of this Statement)

     

    Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

     

    ☐Rule 13d-1(b)

     

    ☒Rule 13d-1(c)

     

      ☐ Rule 13d-1(d)

     

    *The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter disclosures provided in a prior cover page.

     

    The information required on the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (the “Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

     

     

     

     

     

    CUSIP No. M8001Q126 13G Page 2 of 5 Pages

     

    1. NAMES OF REPORTING PERSON

    Aharon Lukach
    2.

    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP
    (See Instructions)

    (a) ☐

    (b) ☐

    3.

    SEC USE ONLY

     

     

    4. CITIZENSHIP OR PLACE OF ORGANIZATION
     
    Israel

    NUMBER OF
    SHARES
    BENEFICIALLY
    OWNED BY
    EACH
    REPORTING
    PERSON WITH
    5.

    SOLE VOTING POWER
     

    471,538 (1)

    6. SHARED VOTING POWER
     
    0
    7.

    SOLE DISPOSITIVE POWER
     

    471,538 (1)

    8. SHARED DISPOSITIVE POWER
     
    0

    9.

    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

     

    471,538 (1)

    10.

    CHECK IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES
    (see instructions)    

    ☐

    11.

    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)

     

    9.4% (2)

    12. TYPE OF REPORTING PERSON (see instructions)

    IN

     

    (1)Includes 207,900 ordinary shares of the Issuer underlying currently exercisable warrants held by the Reporting Person.

     

    (2)Percentage is based on 4,797,252 ordinary shares of the Issuer that were outstanding as of March 6, 2024 (as well as 207,900 additional ordinary shares of the Issuer underlying warrants held by the Reporting Person), based on information contained in the Issuer’s Annual Report on Form 20-F for the year ended December 31, 2023, filed with the SEC on March 6, 2024.

     

     

     

     

    CUSIP No. M8001Q126 13G Page 3 of 5 Pages

     

    Item 1.

     

    (a)

    Name of Issuer

    PolyPid Ltd. (the “Issuer”)

       
    (b)

    Address of Issuer’s Principal Executive Offices
    18 Hasivim Street

    Petach Tikva 495376, Israel

     

    Item 2.

     

    (a)

     

     

    (b)

    Name of Person Filing

    Aharon Lukach

     

    Address of Principal Business Office or, if None, Residence:

     Eli Cohen 9, Tel Aviv, Israel, 6963005.

       
    (c) Citizenship:
    The Reporting Person is a citizen of the State of Israel.
       
    (d) Title of Class of Securities
    Ordinary shares, no par value per share (“Ordinary Shares”).
       
    (e) CUSIP Number
    M8001Q126

     

    Item 3. If this statement is filed pursuant to §§240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:

     

    (a) ☐ Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o).
         
    (b) ☐ Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c).
         
    (c) ☐ Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c).
         
    (d) ☐ Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8).
         
    (e) ☐ An investment adviser in accordance with §240.13d-1(b)(1)(ii)(E);
         
    (f) ☐ An employee benefit plan or endowment fund in accordance with §240.13d-1(b)(1)(ii)(F);
         
    (g) ☐ A parent holding company or control person in accordance with §240.13d-1(b)(1)(ii)(G);
         
    (h) ☐ A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);
         
    (i) ☐ A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);
         
    (j) ☐ A non-U.S. institution in accordance with § 240.13d–1(b)(1)(ii)(J);
         
    (k) ☐ Group, in accordance with §240.13d-1(b)(1)(ii)(K).

     

    If filing as a non-U.S. institution in accordance with § 240.13d–1(b)(1)(ii)(J), please specify the type of institution: ________

     

    Not applicable.

     

     

     

     

    CUSIP No. M8001Q126 13G Page 4 of 5 Pages

     

    Item 4. Ownership.

     

    (a) (b) Number and percentage of Issuer Ordinary Shares beneficially owned by each Reporting Person:

     

    Reporting Person  Number of
    Ordinary
    Shares
       Percentage
    of Class
     
    Aharon Lukach   471,538    9.4%

     

    (a) Number of shares as to which the Reporting Person has:
         
      (i)

    Sole power to vote or to direct the vote: 471,538

     

      (ii) Shared power to vote or to direct the vote: 0
         
      (iii) Sole power to dispose or to direct the disposition of: 471,538
         
      (iv) Shared power to dispose or to direct the disposition of: 0

     

    Based on the Form 20-F filed by the Issuer on March 6, 2024, there were 4,797,252 Ordinary Shares issued and outstanding as of March 6, 2024.

     

    Item 5. Ownership of Five Percent or Less of a Class.

     

    Not applicable.

     

    Item 6. Ownership of More than Five Percent on Behalf of Another Person. 

     

    Not applicable.

     

    Item 7. Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on By the Parent Holding Company. 

     

    Not applicable.

     

    Item 8. Identification and Classification of Members of the Group.

     

    Not applicable.

     

    Item 9. Notice of Dissolution of Group.

     

    Not applicable.

     

    Item 10. Certification.

     

    By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer or the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under § 240. 14a-11.

     

     

     

     

    CUSIP No. M8001Q126 13G Page 5 of 5 Pages

     

    SIGNATURE

     

    After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

     

      Aharon Lukach 
       
      By:  /s/ Aharon Lukach
      Date: April 1, 2024

     

     

     

     

    Get the next $PYPD alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $PYPD

    DatePrice TargetRatingAnalyst
    6/5/2025$9.00Buy
    Roth Capital
    6/2/2025$11.00Buy
    H.C. Wainwright
    1/28/2025$13.00Buy
    Rodman & Renshaw
    2/11/2022$23.00 → $17.00Strong Buy
    Raymond James
    9/14/2021$14.00Market Outperform
    JMP Securities
    7/30/2021$24.00Overweight
    Cantor Fitzgerald
    More analyst ratings

    $PYPD
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • PolyPid to Host Conference Call and Webcast to Discuss D-PLEX₁₀₀ SHIELD II Phase 3 Trial Topline Results on Monday, June 9, 2025

      PETACH TIKVA, Israel, June 06, 2025 (GLOBE NEWSWIRE) -- PolyPid Ltd. (NASDAQ:PYPD), ("PolyPid" or the "Company"), a late-stage biopharma company aiming to improve surgical outcomes, today announced that it will host a conference call and webcast to report topline data for the SHIELD II Phase 3 trial, evaluating D-PLEX100 for the prevention of surgical site infections in patients undergoing abdominal colorectal surgery, on Monday, June 9, at 8:30 a.m. ET. To ensure you are connected prior to the beginning of the call, PolyPid suggests registering a minimum of 5 minutes before the start of the call. Conference Call Dial-In & Webcast Information: Date: Monday, June 9, 2025Time:8:30 AM Easte

      6/6/25 4:05:00 PM ET
      $PYPD
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • PolyPid to Participate in the Lytham Partners Spring 2025 Investor Conference on May 29, 2025

      PETACH TIKVA, Israel, May 20, 2025 (GLOBE NEWSWIRE) -- PolyPid Ltd. (NASDAQ:PYPD) ("PolyPid" or the "Company"), a late-stage biopharma company aiming to improve surgical outcomes, will participate in a webcast presentation and host one-on-one meetings with investors at the Lytham Partners Spring 2025 Investor Conference, taking place virtually on Thursday, May 29, 2025. Company Webcast The webcast presentation will take place at 10:15 a.m. ET on Thursday, May 29, 2025. The webcast can be accessed by visiting the conference home page at https://lythampartners.com/spring2025/ or directly at https://app.webinar.net/QyL1ZkGZK8z. The webcast will also be available for replay following the

      5/20/25 7:00:00 AM ET
      $PYPD
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • PolyPid Provides Corporate Update and Reports First Quarter 2025 Financial Results

      PolyPid Successfully Completed Enrollment in Phase 3 SHIELD II Trial of D-PLEX100, with Top-Line Results Anticipated in Current Quarter Company Continues to Advance Regulatory Submission Preparations, Commercial Launch Preparations and Partnering Discussions Conference Call Scheduled for Today at 8:30 AM ET PETACH TIKVA, Israel, May 14, 2025 (GLOBE NEWSWIRE) -- PolyPid Ltd. (NASDAQ:PYPD) ("PolyPid" or the "Company"), a late-stage biopharma company aiming to improve surgical outcomes, today provided a corporate update and reported financial results for the three months ended March 31, 2025. Recent Corporate Highligh

      5/14/25 7:00:00 AM ET
      $PYPD
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $PYPD
    Leadership Updates

    Live Leadership Updates

    See more
    • PolyPid Announces the Addition of Dr. Nurit Tweezer-Zaks to its Board of Directors

      PETACH TIKVA, Israel, Nov. 07, 2023 (GLOBE NEWSWIRE) -- PolyPid Ltd. (NASDAQ:PYPD) ("PolyPid" or the "Company"), a late-stage biopharma company aiming to improve surgical outcomes, today announced the appointment of Nurit Tweezer-Zaks, M.D., M.B.A, to its Board of Directors, effective November 6, 2023, following the retirement of Anat Tsour Segal. Dr. Tweezer-Zaks is a biopharmaceutical industry veteran with extensive executive business development, clinical, and R&D expertise. She is an experienced sector investor and was a practicing physician for nearly 15 years. "We are thrilled to welcome Dr. Tweezer-Zaks to the PolyPid Board. She has had a distinguished career as a practicing physic

      11/7/23 7:00:00 AM ET
      $PYPD
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • PolyPid Appoints UCSF Brain Tumor Center Director Mitchel S. Berger, M.D., to Oncology Advisory Board

      Dr. Berger Brings Extensive Expertise in Deep Brain Tumor Treatment The Company Expects to Initiate a Phase 1/2 Clinical Trial of OncoPLEX for Brain Tumors by the end of 2022 PETAH TIKVA, Israel, Jan. 04, 2022 (GLOBE NEWSWIRE) -- PolyPid Ltd. (NASDAQ:PYPD) ("PolyPid" or the "Company"), a phase 3 biopharmaceutical company focused on developing targeted, locally administered, and prolonged-release therapeutics using its proprietary PLEX technology, today announced the appointment of Mitchel S. Berger, M.D., to its Oncology Advisory Board. Dr. Berger is the Berthold and Belle N. Guggenhime Professor of the Department of Neurological Surgery at the University of California, San Francisco (U

      1/4/22 7:30:00 AM ET
      $PYPD
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • PolyPid Announces Planned CEO Transition

      PETAH TIKVA, Israel, Jan. 03, 2022 (GLOBE NEWSWIRE) -- PolyPid Ltd. (NASDAQ:PYPD) ("PolyPid" or the "Company"), a Phase 3 biopharmaceutical company focused on developing targeted, locally administered, and prolonged-release therapeutics using its proprietary PLEX technology, today announced that its Board of Directors has appointed Dikla Czaczkes Akselbrad, currently the Company's Executive Vice President and Chief Financial Officer, as PolyPid's Chief Executive Officer, effective July 1, 2022. Amir Weisberg, who currently serves as Chief Executive Officer and a director, will direct a transition period with Ms. Czaczkes Akselbrad beginning on April 1, 2022, and will retire from the Chief

      1/3/22 7:30:00 AM ET
      $PYPD
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $PYPD
    SEC Filings

    See more
    • SEC Form 6-K filed by PolyPid Ltd.

      6-K - PolyPid Ltd. (0001611842) (Filer)

      5/30/25 4:05:39 PM ET
      $PYPD
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 6-K filed by PolyPid Ltd.

      6-K - PolyPid Ltd. (0001611842) (Filer)

      5/21/25 4:05:07 PM ET
      $PYPD
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 6-K filed by PolyPid Ltd.

      6-K - PolyPid Ltd. (0001611842) (Filer)

      5/14/25 7:13:44 AM ET
      $PYPD
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $PYPD
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Roth Capital initiated coverage on PolyPid Ltd. with a new price target

      Roth Capital initiated coverage of PolyPid Ltd. with a rating of Buy and set a new price target of $9.00

      6/5/25 7:35:43 AM ET
      $PYPD
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • H.C. Wainwright resumed coverage on PolyPid Ltd. with a new price target

      H.C. Wainwright resumed coverage of PolyPid Ltd. with a rating of Buy and set a new price target of $11.00

      6/2/25 8:53:56 AM ET
      $PYPD
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Rodman & Renshaw initiated coverage on PolyPid Ltd. with a new price target

      Rodman & Renshaw initiated coverage of PolyPid Ltd. with a rating of Buy and set a new price target of $13.00

      1/28/25 7:16:12 AM ET
      $PYPD
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $PYPD
    Financials

    Live finance-specific insights

    See more
    • PolyPid to Host Conference Call and Webcast to Discuss D-PLEX₁₀₀ SHIELD II Phase 3 Trial Topline Results on Monday, June 9, 2025

      PETACH TIKVA, Israel, June 06, 2025 (GLOBE NEWSWIRE) -- PolyPid Ltd. (NASDAQ:PYPD), ("PolyPid" or the "Company"), a late-stage biopharma company aiming to improve surgical outcomes, today announced that it will host a conference call and webcast to report topline data for the SHIELD II Phase 3 trial, evaluating D-PLEX100 for the prevention of surgical site infections in patients undergoing abdominal colorectal surgery, on Monday, June 9, at 8:30 a.m. ET. To ensure you are connected prior to the beginning of the call, PolyPid suggests registering a minimum of 5 minutes before the start of the call. Conference Call Dial-In & Webcast Information: Date: Monday, June 9, 2025Time:8:30 AM Easte

      6/6/25 4:05:00 PM ET
      $PYPD
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • PolyPid Provides Corporate Update and Reports First Quarter 2025 Financial Results

      PolyPid Successfully Completed Enrollment in Phase 3 SHIELD II Trial of D-PLEX100, with Top-Line Results Anticipated in Current Quarter Company Continues to Advance Regulatory Submission Preparations, Commercial Launch Preparations and Partnering Discussions Conference Call Scheduled for Today at 8:30 AM ET PETACH TIKVA, Israel, May 14, 2025 (GLOBE NEWSWIRE) -- PolyPid Ltd. (NASDAQ:PYPD) ("PolyPid" or the "Company"), a late-stage biopharma company aiming to improve surgical outcomes, today provided a corporate update and reported financial results for the three months ended March 31, 2025. Recent Corporate Highligh

      5/14/25 7:00:00 AM ET
      $PYPD
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • PolyPid to Report First Quarter 2025 Financial Results and Operational Highlights on May 14, 2025

      PETACH TIKVA, Israel, April 29, 2025 (GLOBE NEWSWIRE) -- PolyPid Ltd. (NASDAQ:PYPD) ("PolyPid" or the "Company"), a late-stage biopharma company aiming to improve surgical outcomes, today announced that it will report its first quarter 2025 financial results and operational highlights before the open of the U.S. financial markets on Wednesday, May 14, 2025. The Company will host a conference call and webcast at 8:30 AM Eastern Time to discuss the results and provide an update on business operations. To ensure you are connected prior to the beginning of the call, PolyPid suggests registering a minimum of 5 minutes before the start of the call. For those not planning to ask a question of ma

      4/29/25 7:00:00 AM ET
      $PYPD
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $PYPD
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • Amendment: SEC Form SC 13G/A filed by PolyPid Ltd.

      SC 13G/A - PolyPid Ltd. (0001611842) (Subject)

      12/12/24 7:05:07 AM ET
      $PYPD
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Amendment: SEC Form SC 13G/A filed by PolyPid Ltd.

      SC 13G/A - PolyPid Ltd. (0001611842) (Subject)

      11/29/24 1:20:33 PM ET
      $PYPD
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Amendment: SEC Form SC 13G/A filed by PolyPid Ltd.

      SC 13G/A - PolyPid Ltd. (0001611842) (Subject)

      10/28/24 4:01:03 PM ET
      $PYPD
      Biotechnology: Pharmaceutical Preparations
      Health Care